A Director at Amphastar Pharmaceuticals is Exercising Options

By Carrie Williams

Today, a Director at Amphastar Pharmaceuticals, Richard Prins, exercised options of Amphastar Pharmaceuticals for $330.3K.

Following Richard Prins’ last AMPH Sell transaction on August 16, 2017, the stock climbed by 4.9%. This is Prins’ first transaction since reporting a Sell transaction on IGC back in December 2017

The company has a one-year high of $20.45 and a one-year low of $13.15. AMPH’s market cap is $922.7M and the company has a P/E ratio of 212.71. Currently, Amphastar Pharmaceuticals has an average volume of 393.4K.

Based on 5 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $23.00, reflecting a -13.4% downside.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.